Clinical Trials Directory

Trials / Conditions / Relapse Leukemia

Relapse Leukemia

16 registered clinical trials studyying Relapse Leukemia — 7 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Study of Revumenib and Mezigdomide in People With Leukemia
NCT07356154
Memorial Sloan Kettering Cancer CenterPhase 1 / Phase 2
Not Yet RecruitingEfficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML
NCT07091006
Ruijin HospitalPhase 2
RecruitingPhase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HS
NCT06839456
Children's Hospital of PhiladelphiaPhase 1 / Phase 2
Not Yet RecruitingEfficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
NCT06385808
First Affiliated Hospital Xi'an Jiaotong UniversityN/A
RecruitingSafety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmac
NCT06006403
Chongqing Precision Biotech Co., LtdPhase 1 / Phase 2
RecruitingPharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
NCT05512169
University of Geneva, Switzerland—
CompletedPhase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT04835519
Beijing Boren HospitalPhase 1 / Phase 2
UnknownAllogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT05164042
Shenzhen University General HospitalPhase 1 / Phase 2
RecruitingObservational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clin
NCT04282811
Gruppo Italiano Malattie EMatologiche dell'Adulto—
CompletedDose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in P
NCT04139434
Newave Pharmaceutical IncPhase 1
UnknownImmunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation
NCT03964922
Central Hospital, Nancy, FranceN/A
UnknownDecitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia
NCT03799224
Peking University People's HospitalPhase 2 / Phase 3
UnknownAntiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Follow
NCT03091933
Ciusss de L'Est de l'Île de MontréalPhase 1 / Phase 2
UnknownCladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
NCT03181815
Sun Yat-sen UniversityPhase 2
CompletedOutcome Following Truncation of Asparaginase
NCT03987542
Birgitte Klug Albertsen—
CompletedRandomized Study of HLA-mismatched DSI to Treat Relapse Leukemia After HLA- Matched Transplantation
NCT02028650
huishengai—